World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 84 15030 14151 496 484 431 27597

Anna K. Nowak publications per year

The chart shows the history of publications by Anna K. Nowak between 1999 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Anna K. Nowak published across 27 years, from 1999 to 2025, averaging 20.4 papers a year. Output peaked at 46 publications in 2024. 76 of the 550 publications appeared in the last two years.

No. of publications
10 20 30 40
Bar chart. Horizontal axis: year, 1999 to 2025. Vertical axis: number of publications, 0 to 46. Peak 46 publications in 2024. 1999: 1 publication 2000: 0 publications 2001: 0 publications 2002: 3 publications 2003: 4 publications 2004: 11 publications 2005: 7 publications 2006: 8 publications 2007: 11 publications 2008: 8 publications 2009: 10 publications 2010: 17 publications 2011: 15 publications 2012: 18 publications 2013: 24 publications 2014: 26 publications 2015: 26 publications 2016: 32 publications 2017: 42 publications 2018: 25 publications 2019: 32 publications 2020: 29 publications 2021: 45 publications 2022: 40 publications 2023: 40 publications 2024: 46 publications 2025: 30 publications
1999 2025

550 publications in total across all disciplines

View publications per year as a table
Anna K. Nowak: publications per year, 1999 to 2025
Year Publications
1999 1
2000 0
2001 0
2002 3
2003 4
2004 11
2005 7
2006 8
2007 11
2008 8
2009 10
2010 17
2011 15
2012 18
2013 24
2014 26
2015 26
2016 32
2017 42
2018 25
2019 32
2020 29
2021 45
2022 40
2023 40
2024 46
2025 30
Total 550
Download as CSV

Anna K. Nowak publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Anna K. Nowak sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 421–440 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 431 publications — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806 431
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Anna K. Nowak D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Anna K. Nowak sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 84–85 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003 84
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Anna K. Nowak is affiliated with the University of Western Australia in Australia. Their research primarily focuses on medicine, with a significant specialization in pulmonary and respiratory medicine, oncology, genetics, radiology, nuclear medicine and imaging, and immunology.

The scientist's main fields of study include:

  • Medicine

Subfields of study encompass:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Genetics
  • Radiology, Nuclear Medicine and Imaging
  • Immunology

Research topics covered by their work include:

  • Occupational and environmental lung diseases
  • Pleural and Pulmonary Diseases
  • Glioma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Palliative Care and End-of-Life Issues
  • Cancer Research and Treatments
  • Immunotherapy and Immune Responses

Nowak has contributed to a number of recent papers, among them:

  • First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial, 2021, The Lancet
  • Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study, 2021, The Lancet Oncology
  • First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743, 2022, Annals of Oncology
  • Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Human prefrontal cortex gene regulatory dynamics from gestation to adulthood at single-cell resolution, 2022, Cell

Frequent co-authors collaborating with Nowak include:

  • W. Joost Lesterhuis
  • Georgia Halkett
  • Richard Lake
  • Alistair Cook
  • Haryana M. Dhillon

Common publication venues where Nowak's work appears are:

  • Journal of Thoracic Oncology
  • Neuro-Oncology Practice
  • Neuro-Oncology
  • Annals of Oncology
  • Journal of Clinical Oncology

Best Publications

  • The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

    Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta

  • First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

    Paul Baas;Arnaud Scherpereel;Anna K Nowak;Nobukazu Fujimoto

  • The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer

    William D. Travis;Hisao Asamura;Alexander A. Bankier;Mary Beth Beasley

  • Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

    M.J. Byrne;Anna Nowak;Anna Nowak

  • Mesothelin-family proteins and diagnosis of mesothelioma.

    Bruce W S Robinson;Jenette Creaney;Richard Lake;Anna Nowak

  • Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells

    Anna K Nowak;Richard A Lake;Amanda L Marzo;Amanda L Marzo;Bernadette Maree Scott;Bernadette Maree Scott

  • Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

    Anna K Nowak;Bruce W S Robinson;Richard A Lake

  • Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

    Michele Maio;Arnaud Scherpereel;Luana Calabrò;Joachim Aerts

  • Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

    Martin J van den Bent;Brigitta Baumert;Sara C Erridge;Michael A Vogelbaum;Michael A Vogelbaum

  • Gemcitabine Exerts a Selective Effect on the Humoral Immune Response Implications for Combination Chemo-immunotherapy

    Anna K Nowak;Bruce W S Robinson;Richard A Lake

  • A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma

    A K Nowak;M J Byrne;R Williamson;G Ryan

  • Taxanes for adjuvant treatment of early breast cancer

    Thomas Ferguson;Nicholas Wilcken;Rosemary Vagg;Davina Ghersi

  • Guidelines for the diagnosis and treatment of malignant pleural mesothelioma

    Nico van Zandwijk;Christopher Clarke;Douglas Henderson;A William Musk

  • The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

    Frank C. Detterbeck;Wilbur A. Franklin;Andrew G. Nicholson;Nicolas Girard

  • Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans

    Roslyn J. Francis;Michael J. Byrne;Agatha A. van der Schaaf;Jan A. Boucek

  • The IASLC Lung Cancer Staging Project: Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming (Eighth) Edition of the TNM Classification of Lung Cancer

    Frank C. Detterbeck;Kari Chansky;Patti Groome;Vanessa Bolejack

  • Glioblastoma stem-like cells: at the root of tumor recurrence and a therapeutic target

    Melanie Jackson;Foteini Hassiotou;Anna Nowak

  • Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.

    W. Joost Lesterhuis;Anthony Bosco;Michael J. Millward;Michael J. Millward;Michael Small;Michael Small

  • The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification

    Frank C. Detterbeck;Andrew G. Nicholson;Wilbur A. Franklin;Edith M. Marom

  • Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

    Martin J van den Bent;C Mircea S Tesileanu;Wolfgang Wick;Marc Sanson

Frequent Co-Authors

Richard A. Lake
Richard A. Lake University of Western Australia
Bruce W. S. Robinson
Bruce W. S. Robinson University of Western Australia
Hedy L. Kindler
Hedy L. Kindler University of Chicago
Arthur W. Musk
Arthur W. Musk University of Western Australia
Paul Baas
Paul Baas Antoni van Leeuwenhoek Hospital
Max Bulsara
Max Bulsara University of Notre Dame Australia
Harvey I. Pass
Harvey I. Pass New York University
Robert U. Newton
Robert U. Newton Edith Cowan University
John Simes
John Simes University of Sydney
Valerie W. Rusch
Valerie W. Rusch Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re thinking about studying Medicine in the USA, there are several related online degree options and career pathways worth considering. For those interested in healthcare leadership or management roles, pursuing a health care administration degree online can provide a strong foundation in business, policy, and operations within medical settings.

Registered nurses who want to advance their practice can choose an rn to np bridge program, which helps RNs gain a master’s degree and become nurse practitioners more efficiently. For students interested in preventative health, a nutrition bachelor degree online can unlock opportunities in dietary planning, public health, and wellness education.

Finally, those wanting to take on executive roles in healthcare systems should look for a cahme accredited online mha. These programs provide credible, flexible training for aspiring healthcare administrators. With so many pathways available, students can match their interests and career goals with the right program—often without stepping foot on campus.

Best Scientists Citing Anna K. Nowak

Trending Scientists

Recently Published Articles